Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Phenylacetic acid metabolic genes are associated with Mycobacteroides abscessus dominant circulating clone 1.

Autor: Ross BN; School of Biological Sciences and Center for Microbial Dynamics and Infection, Georgia Institute of Technology, Atlanta, Georgia, USA., Evans E; School of Biological Sciences and Center for Microbial Dynamics and Infection, Georgia Institute of Technology, Atlanta, Georgia, USA., Whiteley M; School of Biological Sciences and Center for Microbial Dynamics and Infection, Georgia Institute of Technology, Atlanta, Georgia, USA.; CF@LANTA-Children's Cystic Fibrosis Center, Atlanta, Georgia, USA.

Publikováno v: Microbiology spectrum [Microbiol Spectr] 2024 Nov 05; Vol. 12 (11), pp. e0133024. Date of Electronic Publication: 2024 Sep 24.

Comparable HIV suppression by pegylated-IFN-α2a or pegylated-IFN-α2b during a 4-week analytical treatment interruption.

Autor: Papasavvas E; The Wistar Institute, Philadelphia., Azzoni L; The Wistar Institute, Philadelphia., Ross BN; The Wistar Institute, Philadelphia., Fair M; The Wistar Institute, Philadelphia., Howell BJ; Merck, Inc., West Point., Hazuda DJ; Merck, Inc., West Point., Mounzer K; Jonathan Lax Immune Disorders Treatment Center, Philadelphia Field Initiating Group for HIV-1 Trials., Kostman JR; John Bell Health Center, Philadelphia Field Initiating Group for HIV-1 Trials., Tebas P; University of Pennsylvania, Department of Medicine, Philadelphia, Pennsylvania, USA., Montaner LJ; The Wistar Institute, Philadelphia.

Publikováno v: AIDS (London, England) [AIDS] 2021 Oct 01; Vol. 35 (12), pp. 2051-2054.

Intact Human Immunodeficiency Virus (HIV) Reservoir Estimated by the Intact Proviral DNA Assay Correlates With Levels of Total and Integrated DNA in the Blood During Suppressive Antiretroviral Therapy.

Autor: Papasavvas E; Wistar Institute, Philadelphia, Pennsylvania, USA., Azzoni L; Wistar Institute, Philadelphia, Pennsylvania, USA., Ross BN; Wistar Institute, Philadelphia, Pennsylvania, USA., Fair M; Wistar Institute, Philadelphia, Pennsylvania, USA., Yuan Z; Wistar Institute, Philadelphia, Pennsylvania, USA., Gyampoh K; Wistar Institute, Philadelphia, Pennsylvania, USA., Mackiewicz A; Wistar Institute, Philadelphia, Pennsylvania, USA., Sciorillo AC; Wistar Institute, Philadelphia, Pennsylvania, USA., Pagliuzza A; University of Montreal, Montreal, Canada., Lada SM; Veterans Affairs San Diego Healthcare System and the University of California, San Diego, California, USA., Wu G; Merck & Co., Inc., Kenilworth, New Jersey, USA., Goh SL; Merck & Co., Inc., Kenilworth, New Jersey, USA., Bahnck-Teets C; Merck & Co., Inc., Kenilworth, New Jersey, USA., Holder DJ; Merck & Co., Inc., Kenilworth, New Jersey, USA., Zuck PD; Merck & Co., Inc., Kenilworth, New Jersey, USA., Damra M; Wistar Institute, Philadelphia, Pennsylvania, USA., Lynn KM; Presbyterian Hospital, University of Pennsylvania hospital, Philadelphia, Pennsylvania, USA., Tebas P; Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Mounzer K; Jonathan Lax Immune Disorders Treatment Center, Philadelphia Field Initiating Group for HIV-1 Trials, Philadelphia, Pennsylvania, USA., Kostman JR; John Bell Health Center, Philadelphia Field Initiating Group for HIV-1 Trials, Philadelphia, Pennsylvania, USA., Abdel-Mohsen M; Wistar Institute, Philadelphia, Pennsylvania, USA., Richman D; Veterans Affairs San Diego Healthcare System and the University of California, San Diego, California, USA., Chomont N; University of Montreal, Montreal, Canada., Howell BJ; Merck & Co., Inc., Kenilworth, New Jersey, USA., Montaner LJ; Wistar Institute, Philadelphia, Pennsylvania, USA.

Publikováno v: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2021 Feb 01; Vol. 72 (3), pp. 495-498.